FIP outcomes in shelter cats classified by FeLV status
Frontiers in veterinary science · 2025
In plain language
This study reviewed records from 170 shelter cats with feline infectious peritonitis (FIP): 104 classified as FeLV-positive and 66 as FeLV-negative. FeLV-positive cats received higher starting doses of GS-441524, making outcomes harder to compare between groups. Some FIP or FeLV diagnoses may have been incorrect because confirmation was limited. The study cannot establish the causal effect of GS-441524 on FIP and does not show that it acts against FeLV or clears the infection.
Scientific detail
This retrospective clinical study, published in Frontiers in veterinary science in 2025 (doi: 10.3389/fvets.2025.1570267), describes feline infectious peritonitis (FIP) outcomes in 170 shelter cats: 104 classified as FeLV-positive and 66 as FeLV-negative. It provides level C evidence concerning limitations of comparisons between these groups.
The authors identified the higher starting doses of GS-441524 given to FeLV-positive cats as a potential influence on outcome comparisons. Unequal drug exposure limits interpretation of similar initial outcomes; this possible confounding does not demonstrate a dose-response relationship. Treatment regimens also varied.
Limited diagnostic confirmation means that some FIP or FeLV diagnoses may have been incorrect. This uncertainty affects group classification and attribution of outcomes, but the study does not quantify how many cats were misclassified. Further limitations include retrospective data collection, shelter admission selection bias, and the absence of necropsies.
There was no untreated comparison that established the causal effect of GS-441524. The study describes FIP outcomes in cats classified as FeLV-positive, but it does not establish antiviral activity of GS-441524 against FeLV or clearance of FeLV infection.
What we know
The study describes FIP outcomes in 170 shelter cats, including 104 classified as FeLV-positive and 66 as FeLV-negative. FeLV-positive cats received higher starting doses of GS-441524, a potential source of confounding in outcome comparisons. Diagnostic confirmation was limited.
What we don't know
The number of cats misclassified for FIP or FeLV is unknown, as is the extent to which dosing differences influenced outcomes. The study does not demonstrate a dose-response relationship or establish the causal effect of GS-441524, its activity against FeLV, or clearance of this infection.
Evidence
EvidenceLevel C — Preliminary evidenceConfidence 100/100
The authors identified higher starting GS-441524 doses in FeLV-positive cats as a potential influence on the comparison of outcomes.
Excerpt verified in the source — verbatim, in the source's own language“For example, FeLV-positive cats were started at a higher dose of GS, potentially leading to a more favorable outcome than if they were treated at the same dose as the FeLV-negative cats.”
Unequal drug exposure limits interpretation of similar initial outcomes. The passage proposes a possible confounding effect; it does not demonstrate a dose-response relationship.
EvidenceLevel C — Preliminary evidenceConfidence 100/100
Some FIP or FeLV diagnoses may have been incorrect because diagnostic confirmation was limited.
Excerpt verified in the source — verbatim, in the source's own language“The diagnosis of FeLV infection was based on the shelter’s protocol for a single antigen test. Necropsies on deceased cats were not performed as the cats lived with foster and adoptive homes. Therefore, it is possible the diagnosis of FIP and/or FeLV was incorrect in some cases.”
Diagnostic uncertainty affects group classification and attribution of outcomes. The study does not quantify how many enrolled cats were misclassified.
Provenance
Source: Spectrum of care approach to animal shelter management of feline infectious peritonitis complicated by feline leukemia virus.
AVA